Results 271 to 280 of about 25,658,089 (295)
Some of the next articles are maybe not open access.
A Patent Review of Topoisomerase I Inhibitors (2016–Present)
Expert Opinion on Therapeutic Patents, 2021Francisco Palacios +2 more
exaly
Mutagenic activity of topoisomerase I inhibitors
Clinical cancer research : an official journal of the American Association for Cancer ResearchTopoisomerase I-directed agents are now in Phase I and II clinical trials and show great promise as potentially important agents for cancer chemotherapy. Because of their mechanism of action they may also be potential mutagens; however, their mutagenicity and oncogenicity still remain to be elucidated.
, Hashimoto, , Chatterjee, , Berger
openaire +1 more source
The clinical pharmacology of topoisomerase I inhibitors.
Seminars in hematology, 1999The Chinese tree Camptotheca acuminata, or Xi Shu, brings us a unique class of chemotherapeutic agents known as the camptothecins. Because the parent compound exhibited excessive toxicity and poor aqueous solubility, synthetic and semisynthetic analogs were developed.
openaire +1 more source
Catalytic Topoisomerase II Inhibitors in Cancer Therapy
Pharmacology & Therapeutics, 2003Alexandre Escargueil +2 more
exaly
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
Chemical Reviews, 2009Yves Pommier
exaly
Contemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy
Chemical Reviews, 2012Christian Bailly
exaly
COVALENT CONJUGATES OF TOPOISOMERASE I AND TOPOISOMERASE II INHIBITORS
1999LEE KUO-HSIUNG +4 more
openaire +3 more sources

